5 Key Takeaways

• 1

  In a phase 1/2 trial of 104 adults with mild-to-moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery, an investigational bimatoprost-eluting IOL was compared with an IOL plu

• 2

  At 12 months, mean IOP reductions were approximately 9 mm Hg, or 33% to 42%, across both bimatoprost-IOL dose groups and the timolol control group.

• 3

  At 12 months, 98% of patients receiving the 78-μg IOL and 96% receiving the 39-μg IOL remained free of additional IOP-lowering medication; control patients continued assigned timolol.

• 4

  Adverse events occurred in 41% and 43% of patients in the 78-μg and 39-μg IOL groups, respectively, and 37% of controls; no serious events, secondary surgeries, or explantations were reported.

• 5

  The 12-month findings are interim, longer follow-up is needed, and the investigational IOL has not received FDA approval.